> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Blocking Drug Info Consumers Need: Report
- URL: https://www.fdaweb.com/fda-blocking-drug-info-consumers-need-report/
- Published: 2025-10-23T12:00:00.000Z
- Updated: 2026-09-14T15:24:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160095

The investigative newsroom *ProPublica* says FDA is keeping vital information about issues in generic drug foreign manufacturing from doctors, pharmacists, and patients who could use the information to make more informed decisions. One of the report’s concerns is that for decades, the agency has redacted the names of generic drugs from inspection reports for foreign manufacturing facilities that have safety and quality violations.

“The practice,” the report says, “has prevented patients, doctors, and pharmacists from knowing whether manufacturing failures have made medications ineffective or unsafe.”

*ProPublica* also says consumers are limited in what they can learn about the quality of their drugs because labels on pill bottles often don’t list the manufacturer or the factory’s address.

The report says that while there is no specific requirement that FDA block out drug names on inspection reports about foreign facilities, the agency has preemptively kept that information hidden, invoking a cautious interpretation of a law that requires the government to protect trade secrets.

“FDA told *ProPublica* that divulging drug names on its inspection reports would violate federal law that protects confidential commercial information,” the report says. “The agency said it only releases the information with approval from drug companies or in cases where companies have already made the details public.”

Responding to a *ProPublica* request for comment, former FDA associate commissioner **Peter Lurie** said, “The whole thing is rendered impotent if you take out the most critical piece of information, which is, what drug is it. You’re left with this kind of vague accusation on which nobody can act because nobody has enough information to be able to do anything.”

Former CDER director **Janet Woodcock** told the reporters that while she favors releasing drug names, she questions the usefulness of inspection reports for the general public. “You guys think you are like citizen scientists and you can figure out what this means, and it’s just not the case,” she said.

Woodcock also said FDA resisted calls to require manufacturers to put more details on drug labels, saying the agency didn’t want to police thousands of companies to ensure they were providing accurate information. “What benefit would this give you, and is it worth the effort?” she asked. “We didn’t think the juice was worth the squeeze.”

The report notes that FDA has now asked Congress to amend the law to clearly require that labels include the names and addresses of manufacturers as well as the companies that produced a drug’s key ingredients.

“FDA could do even more,” *ProPublica* declares. “Current and former officials acknowledge the agency knows where every drug approved for the U.S. market is made, but does not publish that information on its Web site.” The newsroom says it sued FDA in federal court last year to get access to the internal list of drugs and the factories that make them. “The agency ultimately provided much of the information, but withheld more than 6,000 addresses, saying the companies had hired contractors to make their drugs and that those names and addresses were confidential,” it says. “*ProPublica*’s lawsuit is ongoing.”

The report further faults FDA for no longer releasing complaints from doctors and others that linked specific cases of harm, including hospitalizations and deaths, to drug quality concerns. “FDA had included these reports in a public database of adverse events used by researchers, doctors, and others trying to assess drug safety,” it says. “The agency did not respond to questions about why it made the change.”

*ProPublica* says that last July, FDA commissioner **Marty Makary** promised “radical transparency” and the agency released more information about why it had denied applications for new drugs and biological products. “Nearly seven months into his tenure,” it concludes, “the agency has yet to release detailed information about where generic drugs are being made.”